Last Updated on February 10, 2021 by The Health Master
Global pharma major Lupin Limited has received approval for its tavaborole topical solution, 5%, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Kerydin topical solution, 5%, of Anacor Pharmaceuticals, Inc.
The product will be manufactured at Lupin’s facility in Pithampur, India.
Tavaborole topical solution, 5%, is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to trichophyton rubrum or trichophyton mentagrophytes.
Tavaborole topical solution had estimated annual sales of US$ 76 million in the US, according to IQVIA MAT December 2020.
Also read | Alembic Pharma gets 5 observations from USFDA
Go to main website, click here
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here